Roche reports Phase III emicizumab data in hemophilia A

Roche (SIX:ROG; OTCQX:RHHBY) reported updated data from the Phase III HAVEN 1 trial and interim results from the pediatric Phase III HAVEN 2 study of emicizumab (ACE910) as a prophylaxis for hemophilia A in patients with Factor VIII inhibitors.

On HAVEN 1's primary endpoint, emicizumab significantly reduced annualized bleeding rate vs. on-demand use of bypassing agents (BPAs) (2.9 vs. 23.3 treated bleeds, p<0.0001). Additionally, emicizumab led to a higher proportion of patients with zero bleeds vs. controls (62.9% vs. 5.6%)...